Enhanced Follicular Delivery of Minoxidil to Human Scalp Skin Using Cetesomal Formulation

In this study, the authors highlighted treatments for androgenetic alopecia, noting that combination therapies with drugs like minoxidil and antiandrogens often require at least 6 months for clinical improvement, while also emphasizing the value of patient counseling for informed treatment choices.

This review evaluates 21 studies on minoxidil-induced allergic contact dermatitis, finding that some patients with contact dermatitis symptoms like erythema and pruritus are sensitized to minoxidil or its vehicle components and should consider patch testing and alternative formulations for proper management.

The new minoxidil hydrogel improves delivery and is safe for treating hair loss.

This study discusses the limitations of current FDA-approved treatments for androgenic alopecia, noting significant sexual side effects with oral finasteride and formulation challenges with topical minoxidil, and highlights the potential of nanocarriers to improve drug delivery to hair follicles.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study found that adding hydroxypropyl cellulose to minoxidil formulations significantly increased scalp retention and penetration compared to other formulations, potentially leading to reduced application frequency and improved efficacy.

This review highlights that androgenetic alopecia significantly impacts psychological well-being and quality of life, emphasizing the need for integrated psychological support alongside dermatological treatment.

In this study, researchers developed and validated a rapid and robust chromatographic method to assess the concentration of Minoxidil and Finasteride in a new topical formulation for alopecia, demonstrating its ability to distinguish between different types of formulations using in vitro diffusion data.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study found that nanoemulsions incorporating skin penetration enhancers significantly increased the permeation of minoxidil through human skin compared to aqueous control solutions.

In this study, minoxidil significantly downregulated interleukin-1 alpha expression in human keratinocyte cells, suggesting an anti-inflammatory effect that may be a mechanism of action in treating alopecia.

This review discusses various classification systems for male-pattern hair loss, comparing their detail, practicality, and reproducibility, and reports no new clinical outcomes.

This study developed minoxidil sulphate-loaded chitosan nanoparticles that doubled drug delivery to hair follicles in vitro compared to a control solution, suggesting potential for improved alopecia treatment.

This research reported that squarticles, nanoparticles made from sebum-derived lipids, enhanced the follicular delivery and skin accumulation of diphencyprone and minoxidil, indicating effective drug deposition with reduced systemic absorption in alopecia treatment.

This study found that the nanostructured lipid carrier gel containing minoxidil showed good consistency and a prolonged drug release in vitro, suggesting potential for treating alopecia.

This study introduces a novel non-invasive method called "differential stripping" to quantify the penetration of topically applied substances into hair follicles.

This study found that minoxidil penetration through the skin increased with higher ethanol content and occlusion, with the highest penetration observed at 90% ethanol.

Minoxidil effectively treats severe hypertension but may cause side effects, so careful monitoring is needed.